Suppr超能文献

抗蓖麻毒素重组蛋白疫苗RiVax的临床前毒性和疗效测试。

Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin.

作者信息

Smallshaw Joan E, Richardson James A, Pincus Seth, Schindler John, Vitetta Ellen S

机构信息

The Cancer Immunobiology Center, UT Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd, NB9.210, Dallas, TX 75390-8576, USA.

出版信息

Vaccine. 2005 Sep 15;23(39):4775-84. doi: 10.1016/j.vaccine.2005.04.037.

Abstract

Ricin toxin is a plant-derived ribosome inactivating protein (RIP) of extraordinary toxicity. Vaccination using ricin toxoid or its A chain (RTA) is protective in animals but both vaccines have two potential toxicities, RIP and vascular leak syndrome (VLS). Previously we described three recombinant RTA constructs from which both toxicities were eliminated by site-specific mutations. One mutant, V76M/Y80A, RiVax, has now been further characterized for immunogenicity and toxicity in animals. We have found that RiVax is safe at doses of at least 8 mg in mice, 800-fold higher than the protective dose, and induces neutralizing antibodies in both mice and rabbits.

摘要

蓖麻毒素是一种具有极高毒性的植物源核糖体失活蛋白(RIP)。使用蓖麻类毒素或其A链(RTA)进行疫苗接种在动物中具有保护作用,但这两种疫苗都有两种潜在毒性,即RIP和血管渗漏综合征(VLS)。此前我们描述了三种重组RTA构建体,通过位点特异性突变消除了这两种毒性。其中一种突变体V76M/Y80A,即RiVax,现已在动物中进一步进行免疫原性和毒性特征分析。我们发现,RiVax在小鼠中剂量至少为8 mg时是安全的,比保护剂量高800倍,并且在小鼠和兔子中均能诱导产生中和抗体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验